Juniper is developing proprietary therapeutics to address unmet and underserved medical needs in women’s health.

Our current product pipeline is focused on candidates that employ our proprietary intravaginal ring (IVR) technology for targeted delivery of pharmaceuticals.

2017 pipeline

These candidates leverage the 505(b)(2) pathway; initial human clinical trials are expected to begin at Phase 2.

We are actively evaluating additional pharmaceutical products for both internal development and potential collaborations.  These candidates will be announced as they clear internal development hurdles including filings with the U.S. Patent and Trademark Office, commercial assessments, and clinical development and regulatory planning.

Our product development programs are supported by the cash flow generated by Crinone® and Juniper Pharma Services (JPS), our Nottingham, U.K.-based service business.